Thus, we have to consider two issues: what is the risk level of patients with NF1 and breast cancer for another de novo tumor, and how should we follow-up and treat patients with NF1 after mastectomy considering multiple neoplasms? This evidence concerns the gene NF1 and breast carcinoma.